Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses

Stock Track

Sep 08

Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.

Key highlights from Burning Rock's Q2 2025 earnings report include: - Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million) - Gross profit rose 13.3% to RMB108.1 million (US$15.1 million) - Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million) - Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024

The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1117246220"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117246220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117246220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117246220","market":"hk","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses","media":"Stock Track","content":"<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.</p>\n\n<p>Key highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024</p>\n\n<p>The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-08 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.</p>\n\n<p>Key highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024</p>\n\n<p>The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1117246220","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117246220","pubTimestamp":1757338342,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股赛道|燃石生物大涨7.83%Q2业绩强劲亏损收窄","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.\nKey highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024\nThe company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}